Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3019 in Advanced Malignant Tumors
NCT06943677Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3019 in tumors of the hematopoietic and lymphoid tissues, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 6 more. Started May 2025; status: recruiting.
02
Drugs
TQB3019
03
Conditions
tumors of the hematopoietic and lymphoid tissues
Beyond the preview
Go deeper on NCT06943677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943677.